方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| 风险调整III期临床试验× | 自适应随机临床试验× | |
|---|---|---|
| 领域 | 流行病学 | 流行病学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 1980s–present | Late 1990s–2000s (widespread adoption post-2010) |
| 提出者≠ | Evolving practice; foundational risk-adjustment principles established by Pocock (1983) and extended by numerous trialists | Donald Berry and colleagues; formalized by FDA guidance in 2010 and 2019 |
| 类型≠ | Confirmatory randomized trial with baseline risk stratification and covariate adjustment | Experimental clinical trial design |
| 开创性文献≠ | Pocock, S. J. (1983). Clinical Trials: A Practical Approach. Wiley. ISBN: 978-0471901556 | Berry, D. A. (2006). Bayesian clinical trials. Nature Reviews Drug Discovery, 5(1), 27–36. DOI ↗ |
| 别名 | risk-stratified Phase III trial, covariate-adjusted Phase III RCT, risk-adjusted confirmatory trial, RA-Phase III | adaptive RCT, adaptive trial design, response-adaptive randomization trial, adaptive clinical trial |
| 相关 | 6 | 6 |
| 摘要≠ | A risk-adjusted Phase III clinical trial is a large-scale confirmatory randomized experiment that explicitly incorporates participants' baseline prognostic risk profile into both the randomization process and the primary statistical analysis. By stratifying patients on known risk factors before allocation and adjusting for those factors in the outcome model, the design achieves greater statistical precision, reduces confounding, and produces treatment effect estimates that are more clinically meaningful across patient subgroups. | An adaptive randomized clinical trial (adaptive RCT) is a prospective experimental study that uses pre-specified rules to modify one or more trial aspects — such as sample size, allocation ratios, or treatment arms — based on accumulating data collected during the trial itself, while maintaining statistical validity and integrity of the study. |
| ScholarGate数据集 ↗ |
|
|